Institute of Biosciences, Newcastle University, Newcastle Upon Tyne NE1 3BZ, UK.
Int J Mol Sci. 2021 Jan 5;22(1):455. doi: 10.3390/ijms22010455.
Aberrant glycosylation is a universal feature of cancer cells that can impact all steps in tumour progression from malignant transformation to metastasis and immune evasion. One key change in tumour glycosylation is altered core fucosylation. Core fucosylation is driven by fucosyltransferase 8 (FUT8), which catalyses the addition of α1,6-fucose to the innermost GlcNAc residue of N-glycans. FUT8 is frequently upregulated in cancer, and plays a critical role in immune evasion, antibody-dependent cellular cytotoxicity (ADCC), and the regulation of TGF-β, EGF, α3β1 integrin and E-Cadherin. Here, we summarise the role of FUT8 in various cancers (including lung, liver, colorectal, ovarian, prostate, breast, melanoma, thyroid, and pancreatic), discuss the potential mechanisms involved, and outline opportunities to exploit FUT8 as a critical factor in cancer therapeutics in the future.
糖基化异常是癌细胞的普遍特征,它可以影响肿瘤进展的所有步骤,从恶性转化到转移和免疫逃逸。肿瘤糖基化的一个关键变化是核心岩藻糖基化的改变。核心岩藻糖基化由岩藻糖转移酶 8(FUT8)驱动,该酶催化α1,6-岩藻糖添加到 N-聚糖的最内 GlcNAc 残基上。FUT8 在癌症中经常上调,在免疫逃逸、抗体依赖性细胞毒性(ADCC)以及 TGF-β、EGF、α3β1 整合素和 E-钙黏蛋白的调节中发挥关键作用。在这里,我们总结了 FUT8 在各种癌症(包括肺癌、肝癌、结直肠癌、卵巢癌、前列腺癌、乳腺癌、黑色素瘤、甲状腺癌和胰腺癌)中的作用,讨论了涉及的潜在机制,并概述了未来将 FUT8 作为癌症治疗中关键因素加以利用的机会。